Advertisement


David M. Hyman, MD, on Larotrectinib in TRK Fusion Cancers: Trial Results

2017 ASCO Annual Meeting

Advertisement

David M. Hyman, MD, of Memorial Sloan Kettering Cancer Center, discusses findings on the efficacy of larotrectinib, a selective tropomyosin receptor kinase inhibitor, in adult and pediatric cancers. (Abstract LBA2501)



Related Videos

Kidney Cancer

Primo Lara, MD, on RCC: Expert Perspective on Three Key Papers

Primo Lara, MD, of the University of California, Davis Comprehensive Cancer Center, discusses three top abstracts on treating advanced renal cell carcinoma with epacadostat, pembrolizumab, atezolizumab, bevacizumab, sunitinib, or pazopanib. (Abstracts 4505, 4507, 4515)

Kidney Cancer

Daniel Heng, MD, MPH, and Sumanta K. Pal, MD, on Renal Cell Carcinoma: Expert Perspectives

Daniel Heng, MD, MPH, of the Tom Baker Cancer Centre and the University of Calgary, and Sumanta K. Pal, MD, of the City of Hope, discuss key findings presented at ASCO: adjuvant pazopanib vs placebo after nephrectomy in patients with locally advanced disease (the PROTECT Trial), and adjuvant sunitinib used to treat high-risk disease.

Head and Neck Cancer
Issues in Oncology

Maura L. Gillison, MD, PhD, on HPV and the Value of the Vaccine

Maura L. Gillison, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses her findings on the impact of prophylactic human papillomavirus vaccination on oral HPV infections among young adults in the United States. (Abstract 6003)

Lung Cancer

Taofeek K. Owonikoko, MD, PhD, on SCLC: Results of the ECOG-ACRIN 2511 Trial

Taofeek K. Owonikoko, MD, PhD, of Emory University, discusses study findings on cisplatin and etoposide in combination with veliparib or placebo for extensive stage small cell lung cancer. (Abstract 8505)

Survivorship

Todd M. Gibson, PhD, on Childhood Cancer Survivors: Chronic Disease Trends

Todd M. Gibson, PhD, of St. Jude Children’s Research Hospital, discusses results from the Childhood Cancer Survivor Study, which showed a reduction in serious chronic morbidity measured across 3 decades. (LBA10500)

Advertisement

Advertisement




Advertisement